PETVIVO HOLDINGS, INC. ANNOUNCES CLOSE OF NOTE CONVERSION AGREEMENTS TO EXTINGUISH OVER TWO MILLION DOLLARS OF OUTSTANDING DEBT
PetVivo Holdings (OTCQX: PETV) has successfully executed note conversion agreements with four existing shareholders, converting $2,018,155 of outstanding debt into 3,669,806 shares of common stock. The debt consisted of $1,850,000 in principal plus $168,155 in accrued interest, with conversion prices ranging from $0.50 to $0.75 per share.
The converted debt proceeds were used to commercialize the company's flagship products: SPRYNG® with OsteoCushion® Technology, an injectable veterinary device for joint pain management, and PrecisePRP®, an off-the-shelf platelet-rich plasma product for veterinary use. This debt elimination strengthens PetVivo's balance sheet and enables greater focus on strategic growth initiatives.
[ "Elimination of over $2 million in debt from balance sheet", "Successful conversion of debt to equity strengthens financial position", "No immediate cash outlay required for debt settlement", "Demonstrates shareholder confidence through willingness to convert debt to equity" ]PetVivo Holdings (OTCQX: PETV) ha effettivamente stipulato accordi di conversione delle note con quattro azionisti esistenti, trasformando $2,018,155 di debito pendente in 3,669,806 azioni ordinarie. Il debito era composto da $1,850,000 di capitale più $168,155 di interessi maturati, con prezzi di conversione compresi tra $0.50 e $0.75 per azione.
I fondi derivanti dalla conversione del debito sono stati impiegati per commercializzare i prodotti di punta dell'azienda: SPRYNG® con la tecnologia OsteoCushion®, un dispositivo veterinario iniettabile per la gestione del dolore articolare, e PrecisePRP®, un prodotto pronto all'uso a base di plasma ricco di piastrine per uso veterinario. L'eliminazione di questo debito rafforza il bilancio di PetVivo e permette una maggiore concentrazione su iniziative di crescita strategica.
PetVivo Holdings (OTCQX: PETV) ha ejecutado con éxito acuerdos de conversión de notas con cuatro accionistas existentes, convirtiendo $2,018,155 de deuda pendiente en 3,669,806 acciones comunes. La deuda estaba formada por $1,850,000 de principal más $168,155 de intereses acumulados, con precios de conversión que oscilaban entre $0.50 y $0.75 por acción.
Los fondos derivados de la deuda convertida se utilizaron para comercializar los productos insignia de la empresa: SPRYNG® con la tecnología OsteoCushion®, un dispositivo veterinario inyectable para la gestión del dolor articular, y PrecisePRP®, un producto de plasma rico en plaquetas listo para usar para uso veterinario. Esta eliminación de deuda fortalece el balance de PetVivo y permite un mayor enfoque en iniciativas de crecimiento estratégico.
PetVivo Holdings (OTCQX: PETV)는 네 명의 기존 주주와의 노트 전환 계약을 성공적으로 체결하여 미상환 부채 $2,018,155를 3,669,806주의 보통주로 전환했습니다. 부채는 원금 $1,850,000과 미지급 이자 $168,155로 구성되며, 전환가액은 주당 $0.50에서 $0.75 사이였습니다.
전환된 부채 자금은 회사의 대표 제품들을 상용화하는 데 사용되었습니다: SPRYNG®에 OsteoCushion® 기술을 적용한 관절 통증 관리용 주사형 동물용 의료기기와, PrecisePRP®를 반려동물용으로 사용할 수 있는 즉시 사용 가능한 혈소판 풍부혈장(PRP) 제품입니다. 이 부채 제거는 PetVivo의 재무 상태를 강화하고 전략적 성장 이니셔티브에 더 집중할 수 있게 합니다.
PetVivo Holdings (OTCQX: PETV) a mené à bien des accords de conversion d'obligations avec quatre actionnaires existants, convertissant $2,018,155 de dette en 3,669,806 actions ordinaires. La dette se composait de $1,850,000 en principal plus $168,155 d'intérêts accumulés, avec des prix de conversion allant de $0,50 à $0,75 par action.
Les fonds provenant de la conversion ont été utilisés pour commercialiser les produits phares de l'entreprise: SPRYNG® avec la technologie OsteoCushion®, un dispositif vétérinaire injectable pour la gestion de la douleur des articulations, et PrecisePRP®, un produit prêt à l'emploi à base de plasma riche en plaquettes pour usage vétérinaire. Cette réduction de dette renforce le bilan de PetVivo et permet de se concentrer davantage sur les initiatives de croissance stratégique.
PetVivo Holdings (OTCQX: PETV) hat erfolgreich Wandelvereinbarungen mit vier bestehenden Aktionären getroffen und ausstehende Verbindlichkeiten in Aktien umgewandelt. $2,018,155 Schulden wurden in 3,669,806 Stammaktien konvertiert. Die Verbindlichkeiten bestanden aus $1,850,000 Kapital plus $168,155 aufgelaufenen Zinsen, mit Umwandlungspreisen von $0,50 bis $0,75 pro Aktie.
Die Mittel aus der übernommenen Verschuldung wurden genutzt, um die Flagship-Produkte des Unternehmens zu kommerzialisieren: SPRYNG® mit OsteoCushion®-Technologie, ein injizierbares veterinärmedizinisches Gerät zur Gelenkschmerzbehandlung, und PrecisePRP®, ein fertiges PRP-Produkt für tierärztliche Anwendungen. Diese Schuldenreduzierung stärkt die Bilanz von PetVivo und ermöglicht eine stärkere Fokussierung auf strategische Wachstumsinitiativen.
PetVivo Holdings (OTCQX: PETV) قد نفذت بنجاح اتفاقيات تحويل سندات مع أربعة مساهمين حاليين، محولة $2,018,155 من الدين القائم إلى 3,669,806 من الأسهم العادية. الدين يتألف من $1,850,000 كقيمة أصلية بالإضافة إلى $168,155 فائدة مستحقة، مع أسعار تحويل تتراوح بين $0.50 و $0.75 للسهم الواحد. تم استخدام عائدات الدين المحول لتسويق منتجات الشركة الرائدة: SPRYNG® مع تقنية OsteoCushion®، جهاز بيطري قابل للحقن لإدارة آلام المفاصل، وPrecisePRP®، منتج جاهز للاستخدام يعتمد على البلازما الغنية بالصفائح الدموية للاستخدام البيطري. هذا الإجراء لإلغاء الدين يعزز الميزانية العمومية للشركة ويمكّن من تركيز أكبر على مبادرات النمو الاستراتيجية.
PetVivo Holdings (OTCQX: PETV) 已与四位现有股东成功执行票据转换协议，将 $2,018,155 的未偿债务转换为 3,669,806 股普通股。债务包括本金 $1,850,000 与累计利息 $168,155，转换价格范围为每股 $0.50 至 $0.75。转换后的债务资金用于将公司旗舰产品推向市场：SPRYNG® 及 OsteoCushion® 技术，一种用于关节痛管理的注射式兽用设备，以及< b>PrecisePRP®，一款面向兽医用途的现成血小板富集血浆产品。这笔债务清偿加强了 PetVivo 的资产负债表，并使公司能够更专注于战略增长计划。
- None.
- Significant share dilution with 3,669,806 new shares issued
- Conversion prices ($0.50-$0.75) suggest relatively low valuation
Insights
PetVivo eliminated $2M+ debt through conversion to equity, strengthening its balance sheet to support commercialization efforts.
PetVivo's debt conversion agreement represents a significant $2,018,155 liability reduction, comprising $1,850,000 in principal plus $168,155 in accrued interest. The conversion into 3,669,806 shares at prices between $0.50-$0.75 per share creates a cleaner balance sheet while avoiding immediate cash outlays for debt service.
This restructuring achieves three critical objectives: 1) Reduces leverage ratios, 2) Preserves cash for operations and commercialization efforts, and 3) Demonstrates existing shareholder confidence in the company's long-term prospects. The willingness of four noteholders to convert debt to equity at these price points suggests their belief in potential appreciation beyond the conversion rates.
The transaction does come with dilution considerations, as the 3.67 million new shares increase the outstanding share count. However, this dilution is offset by the removal of interest-bearing obligations that would otherwise consume future cash flows. For an early-stage company commercializing innovative veterinary medical devices like SPRYNG and PrecisePRP, trading debt for equity typically represents a positive financial engineering move.
This restructuring positions PetVivo with enhanced financial flexibility to channel resources toward market penetration for their veterinary products rather than debt servicing, potentially accelerating their path to sustainable revenue growth and operational cash flow.
MINNEAPOLIS, Sept. 30, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW) and its wholly-owned subsidiary PetVivo Animal Health, Inc. (collectively "PetVivo" or the “Company”) an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for horses, dogs and other companion animals announced today that the Company has recently entered into note conversion agreements (“Conversion Agreements”) with four existing shareholders of the Company to convert the outstanding balances of fourteen promissory notes (“Notes”) having an aggregate debt outstanding of
The proceeds from the Notes have been used to assist the Company in the commercialization of its signature products, SPRYNG® with OsteoCushion® Technology and Precise PRP®. Spryng is an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles. The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal’s subsynovial tissue. Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.
PrecisePRP is a first-in-class off-the-shelf platelet-rich plasma (PRP) product designed for use by veterinarians. PrecisePRP is a leucoreduced, allogeneic, pooled, freeze-dried PRP intended to provide a species-specific source of concentrated platelets in plasma for intra-articular administration in dogs and horses. Unlike any PRP mechanical kits currently on the market, PrecisePRP™ does not require a blood draw or centrifugation making it a truly off-the-shelf product that is easy and convenient. Perhaps more important is the uniformity and consistency that PrecisePRP® guarantees. Each vial of PrecisePRP® contains a consistent dose of 4 billion platelets per vial at a concentration of Five Hundred Thousand (500,000) platelets per microliter and is leucoreduced with less than One Thousand Five Hundred (1500) white blood cells per microliter.
“We are very pleased to have successfully completed this note conversion, which eliminates over
For more information about PetVivo Holdings, Inc. please contact info1@petvivo.com or visit https://petvivo.com/ and https://www.sprynghealth.com.
No Offer or Solicitation
Nothing contained herein shall constitute an offer to sell or the solicitation of an offer to buy any security. The shares issued pursuant to the Note Conversion Agreements (“Shares”) were offered and sold to persons reasonably believed to be qualified accredited investors pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The Shares have not been and will not be registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. The issuance of restricted shares of the Company’s common stock upon conversion of the Promissory Notes are exempt from registration under Section 4(a)(2) of the Securities Act.
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCQX: PETV; OTCID: PETVW) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twelve patents and six trade secrets protect the Company's biomaterials, products, production processes and methods of use. The Company’s lead products SPRYNG with OsteoCushion technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses, and PrecisePRP, a first-in-class, off-the-shelf, platelet-rich plasma (PRP) product designed for use by veterinarians, are currently available for commercial sale.
CONTACT:
John Lai, CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
(952) 405-6216
Forward-Looking Statements:
The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2025, and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
FAQ
How much debt did PetVivo Holdings (PETV) convert to equity in September 2025?
What was the conversion price for PETV's debt conversion?
How many new shares did PetVivo (PETV) issue for the debt conversion?
What will PetVivo use the converted debt proceeds for?
What are the main products of PetVivo Holdings (PETV)?
